MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Alto Marketing Ltd
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Thermo Fisher Scientific Maybridge Fragments Selected by Nordlund Centre - Maybridge Ro3 500 Fragment Library to support establishment of new fragment screening-based drug discovery platform
Thermo Fisher Scientific Maybridge Fragments Selected by Nordlund Centre

 

NewswireToday - /newswire/ - Southampton, Hampshire, United Kingdom, 2010/03/11 - Maybridge Ro3 500 Fragment Library to support establishment of new fragment screening-based drug discovery platform.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Thermo Fisher Scientific, the world leader in serving science, today announced that the Nordlund Centre for Biomedical Structural Biology at Nanyang Technological University in Singapore has purchased its Maybridge Ro3 500 Fragment Library. Nordlund will use this “off-the-shelf” set of 500 pharmacophorically-rich Maybridge compounds as a globally renowned benchmark fragment library to optimize structure-based screening methods for a diverse set of drug candidates. The ultimate objective of the project is to understand the optimal screening protocols for different protein target families and to publish these results for the scientific and drug discovery community.

The new Nordlund Centre, based in the prestigious Biopolis hub in Singapore, is headed by Professor Pär Nordlund, a renowned structural biologist and visiting professor from the Karolinska Institute in Stockholm. Through this comparative study, the Nordlund team will establish a platform for the efficient generation of chemical probes using fragment-based methods. The six- to nine-month study will guide researchers and the entire industry on the preferred fragment screening technique for several protein classes.

The study includes seven protein classes, including HsP90. The group will assess fragment binding in each protein class using a range of standard techniques, including ITC, NMR, SPR, DSF and X-ray crystallography.

“We selected the Maybridge Fragment library as a benchmark for our comparative study as it is a globally renowned and industry recognised set of diverse and high-quality compounds,” said Dr. Andreas Larsson, project leader within the Nordlund group. “Of particular interest to us was the validated aqueous solubility data provided by Maybridge scientists, where solubility checks up to five mMol in aqueous phosphate buffer have been measured.”

The Nordlund team features individuals from both academia and the pharmaceutical industry with a broad range of competencies. In addition to fragment-based lead generation, these competencies include: structural biology, high-throughput protein production and crystallography, membrane protein production and biophysical characterisation. Such competencies, in addition to the exceptional protein production facilities at NTU, make this an ideal group for undertaking such a broad-reaching comparative study.

This study also demonstrates the growing interest in fragment-based lead design (FBLD) as a means of accelerating many drug design programmes by complementing more traditional high-throughput or low-content assay screening methods. The Maybridge Ro3 500 Fragment Library, selected from the original Maybridge “Rule-of-Three” (Ro3) compliant set, is designed to be a convenient, cost-effective entry point to fragment screening.

Maybridge is part of Thermo Fisher Scientific, the world leader in serving science.

About Maybridge
Maybridge, part of Thermo Fisher Scientific, is well known for providing highly innovative drug-like molecules and screening compounds for drug discovery and development. With products available for both lab and development scale, they specialize in producing new heterocyclic and phenyl ring-based chemical building blocks, including a unique and expanding range of reactive intermediates. For more information about Maybridge brand products visit our website or call +44 18 40 77 05 67.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of more than $10 billion, we have approximately 35,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Alto Marketing Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Thermo Fisher Scientific Maybridge Fragments Selected by Nordlund Centre

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Leigh Dilley - Alto-Marketing.com 
+44(0)14 8955 7672 sarahp[.]alto-marketing.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Alto Marketing Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Alto Marketing Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan
BASF Launches Hepacor in Switzerland for the Dietary Management of Non-Alcoholic Fatty Liver Disease
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019
Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit Apex Watercraft

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)